Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 15  •  04:00PM ET
1.56
Dollar change
-0.03
Percentage change
-1.89
%
Index- P/E- EPS (ttm)-0.57 Insider Own8.14% Shs Outstand63.21M Perf Week-11.36%
Market Cap98.61M Forward P/E- EPS next Y-1.63 Insider Trans1.98% Shs Float58.06M Perf Month-3.70%
Enterprise Value29.63M PEG- EPS next Q-0.41 Inst Own71.35% Short Float6.48% Perf Quarter2.63%
Income-36.40M P/S0.60 EPS this Y-63.44% Inst Trans-12.30% Short Ratio4.06 Perf Half Y-29.73%
Sales165.49M P/B2.12 EPS next Y7.00% ROA-16.30% Short Interest3.76M Perf YTD-52.00%
Book/sh0.74 P/C0.56 EPS next 5Y- ROE-69.71% 52W High5.10 -69.41% Perf Year-56.91%
Cash/sh2.79 P/FCF- EPS past 3/5Y31.80% 19.47% ROIC-24.43% 52W Low0.99 57.63% Perf 3Y-63.29%
Dividend Est.- EV/EBITDA- Sales past 3/5Y24.64% 18.50% Gross Margin82.34% Volatility6.02% 8.47% Perf 5Y-94.10%
Dividend TTM- EV/Sales0.18 EPS Y/Y TTM73.70% Oper. Margin-47.15% ATR (14)0.14 Perf 10Y-93.98%
Dividend Ex-Date- Quick Ratio5.02 Sales Y/Y TTM303.47% Profit Margin-21.99% RSI (14)43.64 Recom2.50
Dividend Gr. 3/5Y- - Current Ratio5.25 EPS Q/Q35.36% SMA20-7.88% Beta1.62 Target Price3.75
Payout- Debt/Eq2.31 Sales Q/Q105.99% SMA50-3.96% Rel Volume0.99 Prev Close1.59
Employees341 LT Debt/Eq2.20 EarningsAug 14 AMC SMA200-24.97% Avg Volume927.10K Price1.56
IPOOct 10, 2013 Option/ShortYes / Yes EPS/Sales Surpr.-34.66% -29.77% Trades Volume914,797 Change-1.89%
Date Action Analyst Rating Change Price Target Change
Nov-07-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-01-24Downgrade BTIG Research Buy → Neutral
Jul-31-24Downgrade Guggenheim Buy → Neutral
Jul-31-24Downgrade B. Riley Securities Buy → Neutral $18 → $5
May-10-24Downgrade TD Cowen Buy → Hold
May-10-24Downgrade Stifel Buy → Hold $29 → $7
May-10-24Downgrade BMO Capital Markets Outperform → Market Perform $24 → $8
Apr-26-24Initiated B. Riley Securities Buy $25
Apr-09-24Upgrade TD Cowen Hold → Buy
Mar-04-24Reiterated BTIG Research Buy $12 → $24
Sep-02-25 04:30PM
Aug-14-25 05:15PM
04:10PM
04:01PM
Aug-13-25 04:01PM
08:50AM Loading…
08:50AM
Jul-31-25 07:25AM
Jul-29-25 05:10PM
Jun-10-25 07:00AM
Jun-03-25 04:30PM
May-22-25 09:36AM
May-21-25 11:37AM
May-13-25 05:15PM
04:11PM
04:01PM
09:46AM Loading…
May-12-25 09:46AM
07:15AM
May-08-25 07:40AM
May-07-25 05:40PM
May-06-25 04:30PM
May-01-25 04:30PM
Apr-17-25 08:52AM
Apr-03-25 09:35AM
Mar-21-25 02:19PM
12:05PM
09:29AM
03:05AM
Mar-20-25 08:15PM
07:09PM
07:00PM
06:50PM Loading…
06:50PM
04:02PM
10:00AM
Mar-19-25 05:35PM
05:15PM
Mar-06-25 07:30AM
Feb-27-25 07:30AM
Dec-02-24 04:30PM
Nov-06-24 04:30PM
08:51AM
02:25AM
Nov-05-24 10:15PM
08:00PM
07:30PM
06:26PM
04:01PM
Nov-04-24 07:13AM
Oct-30-24 07:30AM
Oct-29-24 04:30PM
Oct-23-24 08:41AM
Oct-22-24 07:30AM
Sep-24-24 05:45AM
Sep-23-24 11:05AM
Sep-20-24 05:06AM
Sep-19-24 01:29PM
Sep-17-24 08:30AM
05:45AM
Sep-15-24 03:00AM
Sep-13-24 08:34AM
Sep-11-24 08:30AM
Sep-08-24 07:10PM
Sep-04-24 03:29PM
Sep-03-24 05:45AM
Sep-02-24 02:05PM
Aug-30-24 09:43AM
Aug-29-24 01:09PM
Aug-27-24 10:48AM
Aug-26-24 03:40PM
Aug-22-24 03:16PM
01:17PM
Aug-21-24 07:05AM
Aug-19-24 04:37PM
Aug-17-24 03:29PM
Aug-16-24 05:45AM
04:26AM
Aug-15-24 02:19PM
Aug-14-24 12:19PM
Aug-13-24 02:31PM
12:45AM
Aug-12-24 10:20AM
Aug-08-24 11:31AM
Aug-07-24 08:53AM
Aug-06-24 09:30PM
05:30PM
04:33PM
04:01PM
Jul-30-24 04:10PM
04:01PM
Jul-24-24 01:29PM
Jul-16-24 03:57PM
Jul-10-24 05:19PM
Jul-03-24 05:34PM
Jun-20-24 01:28PM
Jun-13-24 12:29PM
Jun-11-24 07:45AM
May-29-24 12:44PM
May-25-24 12:00PM
May-17-24 12:50PM
May-16-24 12:59PM
May-13-24 12:30PM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HEIDEN WILLIAM KDirectorAug 19 '25Buy1.5250,50076,76061,500Aug 21 04:19 PM
HEIDEN WILLIAM KDirectorAug 20 '25Buy1.4949,50073,755111,000Aug 21 04:19 PM
Koenig ScottDirectorAug 13 '25Option Exercise0.0052,8290830,244Aug 15 05:05 PM
Bonvini EzioSr VP, Research & CSOFeb 15 '25Option Exercise0.0016,6650124,414Feb 19 04:31 PM
Karrels JamesSVP, CFO and SecretaryFeb 15 '25Option Exercise0.0014,9980192,591Feb 19 04:29 PM
Koenig ScottPresident and CEOFeb 15 '25Option Exercise0.0042,3290777,415Feb 19 04:28 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 15 '25Option Exercise0.0013,332018,858Feb 19 04:25 PM
Risser Eric BlasiusChief Operating OfficerFeb 15 '25Option Exercise0.0016,665062,422Feb 19 04:24 PM
Smith Beth AnnVP, Controller & TreasurerFeb 15 '25Option Exercise0.001,09509,955Feb 19 04:23 PM
Smith Beth AnnVP, Controller & TreasurerFeb 15 '25Sale2.564231,0839,532Feb 19 04:23 PM
Spitznagel ThomasSr VP, Technical OpsFeb 15 '25Option Exercise0.0013,332026,922Feb 19 04:22 PM
Eck Stephen L.Chief Medical OfficerFeb 15 '25Option Exercise0.0016,665034,319Feb 19 04:20 PM
Eck Stephen L.Chief Medical OfficerFeb 08 '25Option Exercise0.0011,168020,966Feb 11 08:34 PM